Identification
- Summary
Threonine is an amino acid commonly found as a component of total parenteral nutrition.
- Brand Names
- Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Nephramine, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %
- Generic Name
- Threonine
- DrugBank Accession Number
- DB00156
- Background
An essential amino acid occurring naturally in the L-form, which is the active form. It is found in eggs, milk, gelatin, and other proteins.
- Type
- Small Molecule
- Groups
- Approved, Nutraceutical
- Structure
Structure for Threonine (DB00156)
- Weight
- Average: 119.1192
Monoisotopic: 119.058243159 - Chemical Formula
- C4H9NO3
- Synonyms
- (2S,3R)-(-)-Threonine
- (2S)-threonine
- 2-Amino-3-hydroxybutyric acid
- L-(-)-Threonine
- L-2-Amino-3-hydroxybutyric acid
- L-alpha-amino-beta-hydroxybutyric acid
- L-Threonin
- L-Threonine
- L-α-amino-β-hydroxybutyric acid
- Thr
- Threonine
- Threoninum
- Treonina
Pharmacology
- Indication
L-Threonine makes up collagen, elastin, and enamel protein. It aids proper fat metabolism in the liver, helps the digestive and intestinal tracts function more smoothly, and assists in metabolism and assimilation.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
L-Threonine is an essential amino acid that helps to maintain the proper protein balance in the body. It is important for the formation of collagen, elastin, and tooth enamel, and aids liver and lipotropic function when combined with aspartic acid and methionine.
- Mechanism of action
L-Threonine is a precursor to the amino acids glycine and serine. It acts as a lipotropic in controlling fat build-up in the liver. May help combat mental illness and may be very useful in indigestion and intestinal malfunctions. Also, threonine prevents excessive liver fat. Nutrients are more readily absorbed when threonine is present.
Target Actions Organism UThreonine--tRNA ligase, cytoplasmic Not Available Humans UThreonine--tRNA ligase, mitochondrial Not Available Humans UBeta-lactamase Toho-1 unknownEscherichia coli - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
Hepatic
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image 2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Threonine (105 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (290 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Dipotassium phosphate (130.5 mg / 100 mL) + Glycine (260 mg / 100 mL) + Histidine (120 mg / 100 mL) + Isoleucine (150 mg / 100 mL) + Leucine (182.5 mg / 100 mL) + Lysine hydrochloride (145 mg / 100 mL) + Magnesium chloride (25.5 mg / 100 mL) + Methionine (100 mg / 100 mL) + Phenylalanine (140 mg / 100 mL) + Proline (170 mg / 100 mL) + Serine (125 mg / 100 mL) + Sodium acetate (170 mg / 100 mL) + Sodium chloride (29.3 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (145 mg / 100 mL) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1996-12-31 2015-08-05 Canada 
2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose Clinimix Threonine (105 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (260 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Dipotassium phosphate (130.5 mg / 100 mL) + Glycine (520 mg / 100 mL) + Histidine (110 mg / 100 mL) + Isoleucine (120 mg / 100 mL) + L-Leucine hydrochloride (155 mg / 100 mL) + Lysine hydrochloride (145 mg / 100 mL) + Magnesium chloride (25.5 mg / 100 mL) + Methionine (145 mg / 100 mL) + Phenylalanine hydrochloride (155 mg / 100 mL) + Proline (105 mg / 100 mL) + Sodium acetate (170 mg / 100 mL) + Sodium chloride (29.3 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (115 mg / 100 mL) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1993-12-31 2015-08-05 Canada 2.5% Travasol Amino Acid Injection Without Electrolytes In 10% Dextrose Quickmix Threonine (105 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (260 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Glycine (520 mg / 100 mL) + Histidine (110 mg / 100 mL) + Isoleucine (120 mg / 100 mL) + L-Leucine hydrochloride (155 mg / 100 mL) + Lysine hydrochloride (195 mg / 100 mL) + Methionine (195 mg / 100 mL) + Phenylalanine hydrochloride (155 mg / 100 mL) + Proline (105 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (115 mg / 100 mL) Solution Intravenous Baxter Corporation Clintec Nutrition Division 1995-12-31 2007-08-02 Canada 2.5%travasol Amino Acid InJ.W.eleC.W.25%dex Threonine (105 mg / 100 mL) + Alanine (520 mg / 100 mL) + Arginine (290 mg / 100 mL) + Dextrose, unspecified form (25 g / 100 mL) + Dipotassium phosphate (130.5 mg / 100 mL) + Glycine (260 mg / 100 mL) + Histidine (120 mg / 100 mL) + Isoleucine (150 mg / 100 mL) + Leucine (182.5 mg / 100 mL) + Lysine hydrochloride (145 mg / 100 mL) + Magnesium chloride (25.5 mg / 100 mL) + Methionine (100 mg / 100 mL) + Phenylalanine (140 mg / 100 mL) + Proline (170 mg / 100 mL) + Serine (125 mg / 100 mL) + Sodium acetate (170 mg / 100 mL) + Sodium chloride (29.3 mg / 100 mL) + Tryptophan (45 mg / 100 mL) + Tyrosine (10 mg / 100 mL) + Valine (145 mg / 100 mL) Liquid Intravenous Clintec Nutrition Company 1996-07-30 1998-08-13 Canada 2.75% Travas. Amino Acid InJ.W.elecw.25%dex Threonine (115.5 mg / 100 mL) + Alanine (570 mg / 100 mL) + Arginine (316 mg / 100 mL) + Dextrose, unspecified form (25 g / 100 mL) + Dipotassium phosphate (261 mg / 100 mL) + Glycine (283 mg / 100 mL) + Histidine (132 mg / 100 mL) + Isoleucine (165 mg / 100 mL) + Leucine (201 mg / 100 mL) + Lysine hydrochloride (159.5 mg / 100 mL) + Magnesium chloride (51 mg / 100 mL) + Methionine (110 mg / 100 mL) + Phenylalanine (154 mg / 100 mL) + Proline (187 mg / 100 mL) + Serine (137.5 mg / 100 mL) + Sodium acetate (215.5 mg / 100 mL) + Sodium chloride (112 mg / 100 mL) + Tryptophan (49.5 mg / 100 mL) + Tyrosine (11 mg / 100 mL) + Valine (159.5 mg / 100 mL) Liquid Intravenous Clintec Nutrition Company 1996-07-30 1998-08-13 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Clinimix Threonine (1.16 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (75.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + Leucine (2.01 g/1L) + Lysine (2.00 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US 
Clinimix Threonine (1.16 g/1L) + Alanine (5.70 g/1L) + Arginine (3.17 g/1L) + Calcium chloride dihydrate (0.33 g/1L) + D-glucose monohydrate (100.00 g/1L) + Dipotassium phosphate (2.61 g/1L) + Glycine (2.84 g/1L) + Histidine (1.32 g/1L) + Isoleucine (1.65 g/1L) + Leucine (2.01 g/1L) + Lysine (2.00 g/1L) + Magnesium chloride hexahydrate (0.51 g/1L) + Methionine (1.10 g/1L) + Phenylalanine (1.54 g/1L) + Proline (1.87 g/1L) + Serine (1.38 g/1L) + Sodium acetate trihydrate (2.16 g/1L) + Sodium chloride (1.12 g/1L) + Tryptophan (0.50 g/1L) + Tyrosine (0.11 g/1L) + Valine (1.60 g/1L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US Clinimix Threonine (3.57 g/2L) + Alanine (17.60 g/2L) + Arginine (9.78 g/2L) + Calcium chloride dihydrate (0.66 g/2L) + D-glucose monohydrate (300.00 g/2L) + Dipotassium phosphate (5.22 g/2L) + Glycine (8.76 g/2L) + Histidine (4.08 g/2L) + Isoleucine (5.10 g/2L) + Leucine (6.20 g/2L) + Lysine (4.93 g/2L) + Magnesium chloride hexahydrate (1.02 g/2L) + Methionine (3.40 g/2L) + Phenylalanine (4.76 g/2L) + Proline (5.78 g/2L) + Serine (4.25 g/2L) + Sodium acetate trihydrate (5.94 g/2L) + Sodium chloride (1.54 g/2L) + Tryptophan (1.53 g/2L) + Tyrosine (0.34 g/2L) + Valine (4.93 g/2L) Solution Intravenous Baxter Healthcare Corporation 2017-10-25 2019-11-30 US FREAMINE III %10 1000 ML(SETLI) Threonine (0.4 %) + Alanine (0.71 %) + Arginine (0.95 %) + Cysteine (0.016 %) + Glycine (1.4 %) + Histidine (0.28 %) + Isoleucine (0.69 %) + Leucine (0.91 %) + Lysine (0.73 %) + Methionine (0.53 %) + Phenylalanine (0.56 %) + Proline (1.12 %) + Serine (0.59 %) + Tryptophan (0.15 %) + Valine (0.66 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2013-01-29 2024-01-23 Turkey 
FREAMINE III %10 1000 ML(SETSIZ) Threonine (0.4 %) + Alanine (0.71 %) + Arginine (0.95 %) + Cysteine (0.016 %) + Glycine (1.4 %) + Histidine (0.28 %) + Isoleucine (0.69 %) + Leucine (0.91 %) + Lysine (0.73 %) + Methionine (0.53 %) + Phenylalanine (0.56 %) + Proline (1.12 %) + Serine (0.59 %) + Tryptophan (0.15 %) + Valine (0.66 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2013-01-29 2024-01-23 Turkey
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- L-alpha-amino acids
- Alternative Parents
- Short-chain hydroxy acids and derivatives / Beta hydroxy acids and derivatives / Fatty acids and conjugates / Secondary alcohols / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines show 2 more
- Substituents
- Alcohol / Aliphatic acyclic compound / Amine / Amino acid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid / Fatty acid / Hydrocarbon derivative / Hydroxy acid show 12 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- aspartate family amino acid, proteinogenic amino acid, L-alpha-amino acid, threonine (CHEBI:16857) / Common amino acids (C00188)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 2ZD004190S
- CAS number
- 72-19-5
- InChI Key
- AYFVYJQAPQTCCC-GBXIJSLDSA-N
- InChI
- InChI=1S/C4H9NO3/c1-2(6)3(5)4(7)8/h2-3,6H,5H2,1H3,(H,7,8)/t2-,3+/m1/s1
- IUPAC Name
- (2S,3R)-2-amino-3-hydroxybutanoic acid
- SMILES
- C[C@@H](O)[C@H](N)C(O)=O
References
- Synthesis Reference
Masato Terasawa, Yukie Satoo, Hideaki Yukawa, "Method for production of l-threonine." U.S. Patent US5019503, issued June, 1967.
US5019503- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000167
- KEGG Drug
- D00041
- KEGG Compound
- C00188
- PubChem Compound
- 6288
- PubChem Substance
- 46506798
- ChemSpider
- 6051
- 10524
- ChEBI
- 16857
- ChEMBL
- CHEMBL291747
- ZINC
- ZINC000000895103
- PharmGKB
- PA451673
- PDBe Ligand
- THR
- Wikipedia
- Threonine
- MSDS
- Download (72.6 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Critically Ill Patients / Starvation 1 4 Completed Treatment Diabetic Nephropathy 1 4 Recruiting Basic Science Healthy Subjects (HS) / Obesity / Type 2 Diabetes Mellitus 1 4 Recruiting Prevention Intestinal Obstruction / Ischemia, Mesenteric / Laparotomy 1 4 Terminated Supportive Care Cancer-related Malnutrition 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Hospira Inc.
- Novis PR Inc.
- Spectrum Pharmaceuticals
- V Sab Medical Labs Inc.
- Dosage Forms
Form Route Strength Solution Parenteral Tablet, coated Oral Tablet Oral Powder Topical Solution Intravenous 10.50 g/1000ml Injection Intravenous 0.5 g/l Injection Intravenous 0.25 g/1000ml Solution, concentrate Intravenous Injection Intravenous 0.52 g/l Injection, solution Intravenous Injection Intravenous 11.000 g/1000ml Solution Intravenous 18.5 g/L Injection Intravenous 5.5 g/1000ml Drug delivery system Oral 0.105 g Injection, emulsion Intravenous Emulsion Intravenous 0.468 g Injection Intravenous 16 g/1000ml Emulsion Parenteral 20.000 g Injection Intravenous 1.6 g/l Injection Intravenous 0.37 g/l Injection, solution, concentrate Intravenous Injection, emulsion Parenteral Emulsion Intravenous 0.466 g Injection, emulsion; injection, solution Intravenous Emulsion Parenteral Emulsion Intravenous Injection, solution Injection, emulsion Intravenous 4.656 g/1000ml Injection, emulsion Intravenous 6.792 g/1000ml Solution Intraperitoneal Injection, solution Intraperitoneal Liquid Hemodialysis Solution Intraperitoneal 0.184 g/l Emulsion Intravenous 176 g/l Emulsion Intravenous 4 g Emulsion Intravenous 3 g Solution Intravenous Tablet Oral 105.000 mg Injection Intravenous 4 g/l Injection Intravenous 0.21 g/100ml Liquid Intravenous Emulsion Intravenous 13.000 g Emulsion Parenteral 42.00 g Injection, emulsion Intravenous 14 g/1000ml Tablet Oral 67.000 mg Injection Intravenous 10.30 g/l Injection Intravenous - Prices
Unit description Cost Unit L-threonine crystal 4.57USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 256 dec °C PhysProp water solubility 9.7E+004 mg/L (at 25 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP -2.94 HANSCH,C ET AL. (1995) logS -0.09 ADME Research, USCD pKa 5.60 Not Available - Predicted Properties
Property Value Source Water Solubility 477.0 mg/mL ALOGPS logP -3 ALOGPS logP -3.5 Chemaxon logS 0.6 ALOGPS pKa (Strongest Acidic) 2.21 Chemaxon pKa (Strongest Basic) 9 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 83.55 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 26.46 m3·mol-1 Chemaxon Polarizability 11.08 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.939 Blood Brain Barrier - 0.6054 Caco-2 permeable - 0.9009 P-glycoprotein substrate Non-substrate 0.7827 P-glycoprotein inhibitor I Non-inhibitor 0.9851 P-glycoprotein inhibitor II Non-inhibitor 0.9902 Renal organic cation transporter Non-inhibitor 0.9634 CYP450 2C9 substrate Non-substrate 0.8233 CYP450 2D6 substrate Non-substrate 0.8832 CYP450 3A4 substrate Non-substrate 0.8021 CYP450 1A2 substrate Non-inhibitor 0.8694 CYP450 2C9 inhibitor Non-inhibitor 0.9362 CYP450 2D6 inhibitor Non-inhibitor 0.9529 CYP450 2C19 inhibitor Non-inhibitor 0.9119 CYP450 3A4 inhibitor Non-inhibitor 0.8683 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9806 Ames test Non AMES toxic 0.9538 Carcinogenicity Non-carcinogens 0.6811 Biodegradation Ready biodegradable 0.844 Rat acute toxicity 1.2108 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9902 hERG inhibition (predictor II) Non-inhibitor 0.9826
Spectra
- Mass Spec (NIST)
- Download (8.11 KB)
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 120.816767 predictedDarkChem Lite v0.1.0 [M-H]- 120.2848401 predictedDarkChem Standard v0.1.0 [M-H]- 119.956867 predictedDarkChem Lite v0.1.0 [M-H]- 119.700967 predictedDarkChem Lite v0.1.0 [M-H]- 122.73663 predictedDeepCCS 1.0 (2019) [M+H]+ 121.030067 predictedDarkChem Lite v0.1.0 [M+H]+ 120.391267 predictedDarkChem Lite v0.1.0 [M+H]+ 120.393167 predictedDarkChem Lite v0.1.0 [M+H]+ 120.298267 predictedDarkChem Lite v0.1.0 [M+H]+ 126.26785 predictedDeepCCS 1.0 (2019) [M+Na]+ 120.314667 predictedDarkChem Lite v0.1.0 [M+Na]+ 119.485367 predictedDarkChem Lite v0.1.0 [M+Na]+ 119.505467 predictedDarkChem Lite v0.1.0 [M+Na]+ 119.449167 predictedDarkChem Lite v0.1.0 [M+Na]+ 135.3771 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Threonine-trna ligase activity
- Specific Function
- Not Available
- Gene Name
- TARS
- Uniprot ID
- P26639
- Uniprot Name
- Threonine--tRNA ligase, cytoplasmic
- Molecular Weight
- 83434.5 Da
References
- Torres-Larios A, Sankaranarayanan R, Rees B, Dock-Bregeon AC, Moras D: Conformational movements and cooperativity upon amino acid, ATP and tRNA binding in threonyl-tRNA synthetase. J Mol Biol. 2003 Aug 1;331(1):201-11. [Article]
- Ruan B, Bovee ML, Sacher M, Stathopoulos C, Poralla K, Francklyn CS, Soll D: A unique hydrophobic cluster near the active site contributes to differences in borrelidin inhibition among threonyl-tRNA synthetases. J Biol Chem. 2005 Jan 7;280(1):571-7. Epub 2004 Oct 26. [Article]
- Cusack S, Yaremchuk A, Krikliviy I, Tukalo M: tRNA(Pro) anticodon recognition by Thermus thermophilus prolyl-tRNA synthetase. Structure. 1998 Jan 15;6(1):101-8. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Threonine-trna ligase activity
- Specific Function
- Not Available
- Gene Name
- TARS2
- Uniprot ID
- Q9BW92
- Uniprot Name
- Threonine--tRNA ligase, mitochondrial
- Molecular Weight
- 81035.345 Da
References
- Caillet J, Graffe M, Eyermann F, Romby P, Springer M: Mutations in residues involved in zinc binding in the catalytic site of Escherichia coli threonyl-tRNA synthetase confer a dominant lethal phenotype. J Bacteriol. 2007 Oct;189(19):6839-48. Epub 2007 Jul 20. [Article]
- Kind
- Protein
- Organism
- Escherichia coli
- Pharmacological action
- Unknown
- Actions
- Unknown
- General Function
- Beta-lactamase activity
- Specific Function
- Has strong cefotaxime-hydrolyzing activity.
- Gene Name
- bla
- Uniprot ID
- Q47066
- Uniprot Name
- Beta-lactamase Toho-1
- Molecular Weight
- 31446.6 Da
References
- Ishii Y, Ohno A, Taguchi H, Imajo S, Ishiguro M, Matsuzawa H: Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli. Antimicrob Agents Chemother. 1995 Oct;39(10):2269-75. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Transporter activity
- Specific Function
- Sodium-independent transporter that mediates the update of aromatic acid. Can function as a net efflux pathway for aromatic amino acids in the basosolateral epithelial cells (By similarity).
- Gene Name
- SLC16A10
- Uniprot ID
- Q8TF71
- Uniprot Name
- Monocarboxylate transporter 10
- Molecular Weight
- 55492.07 Da
References
- Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H: Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biol Chem. 2001 May 18;276(20):17221-8. Epub 2001 Feb 20. [Article]
Drug created at June 13, 2005 13:24 / Updated at January 02, 2024 23:42